What may be next from Bioelectronics Corp (OTCMKTS:BIEL)?
There hasn’t been much development around Bioelectronics Corp (OTCMKTS:BIEL) stock for the entire month that’s gone by. The share kept revolving around a rate of $0.0003 a share. But, with the onset of February, the volume started spiking and what followed ahead was PPS. With the end of first week, the shares of company were trading at a profit of almost 400% with a share price of $0.0015. Since then, Bioelectronics Corp has managed to correct about 35%. At present, the shares are trading for circa $0.001.
Yet, at a price like this, the company’s market capital is as much as $12 million through its 12.6 billion shares outstanding shares. So, can be expect value addition in this exposure? Let us find out.
ActiPatch, company’s lead product has the FDA nod
Bioelectronics Corp has a product portfolio, which is pretty much strong. It has lately gained some ground on backdrop of FDA’s approval to its lead over the counter (OTC) product, ActiPatch, which shall be starting distribution soon.
Company comes with a neuromodulation technology, which means that there is a scope of direct stimulation of nervous system. ActiPatch comes empowered with this technology. It is easier for the companies to seek approvals for such kinds of products because, in order to sell a product like this, a company only needs to prove its safety. This is much sorted than development pathway for new chemical drugs.
With this, it becomes evident that Bioelectronics Corp need not go that extra mile to prove that it different from other treatments available in the market. That is why, there is a hint of upside potential here.
Moreover, ActiPatch has proved itself as an effective treatment for bringing down pain.
So, what’s the takeaway of this scenario? In Q4 2016, the company reported mere $21K cash in hand, which drops a few clues towards near-term dilution. OTC approval is yet another thing that is good enough to be carried ahead. Now, Bioelectronics may have some bright future quarters. And, we look forward to some numbers that indicate optimism around this company.© Copyright 2016 OTC News Magazine. All rights reserved.